New Clinical Trial: New Analytic Tools for aHUS and C3G Diagnosis (NCT05985122)
WHY IT MATTERS
This trial is developing improved diagnostic tests for aHUS and C3G, which could help patients get diagnosed faster and start treatment sooner—critical since these complement-mediated kidney diseases can cause permanent kidney damage if left untreated.
Researchers across 7 European countries are working together to develop better ways to diagnose two rare kidney diseases: atypical hemolytic-uremic syndrome (aHUS) and C3 glomerulonephritis (C3G). This study is enrolling 180 people, including patients with these conditions and healthy volunteers, to test new diagnostic tools that could help doctors identify these diseases more quickly and accurately.
NCT ID: NCT05985122 Status: ACTIVE_NOT_RECRUITING Conditions: Hemolytic-Uremic Syndrome, Membranoproliferative Glomerulonephritis, Healthy Phase: NA Enrollment: 180 Sponsor: Mario Negri Institute for Pharmacological Research Summary: This protocol is part of a larger project, COMPRare (COMPlement-mediated Rare kidney diseases), which has been financed on behalf of the EJP RD (European Joint Programme on Rare Diseases) program of EU and is leaded by a scientific consortium from 7 European countries. The partners (P) of the consortium are: P1. Radboudumc Amalia Children's Hospital (The Netherlands) P2. Semmelweis University (Hungary) P3. Cordeliers Research Center (France) P4. Max Delbruck Center for Molecular Medicine (Germ